Skip to main content
. Author manuscript; available in PMC: 2012 Mar 30.
Published in final edited form as: Nature. 2011 Jul 13;475(7355):231–234. doi: 10.1038/nature10167

Figure 2. In vivo anti-tumor effect of PL.

Figure 2

a, Mammary tumor growth inhibition by PL treatment in MMTV-PyVT transgenic tumor mice. MMTV-PyVT mice spontaneously developed breast adenocarcinoma by ~8 weeks of age. When tumor sizes grew to ~5–6 mm in diameter, the PL (total 2.4 mg/kg), paclitaxel (10 mg/kg) or DMSO (5% V/V) was administered intraperitoneally (i.p.) daily for 13 days (12 mice per group). Mice were then sacrificed and mammary tumors excised and processed for histological examination. b, The size of the grossly dissected tumors was measured. c, Histological morphology of hematoxylin-eosin-stained mammary tissue sections of MMTV-PyVT tumor mice treated with PL or DMSO after 13 days. d, After 13 days of PL treatment (*10 days treatment of paclitaxel was performed due to high toxicity in animals). Values in quantitative bar graphs are mean ± SD of three independent experiments.